title: Can thyroid stimulating hormone levels by TSH (IRMA) predict relapse of thyrotoxicosis following carbimazole treatment?
abstract: Serum thyrotrophin receptor antibody (TRAb) and thyroid stimulating hormone (TSH) (IRMA) levels were measured in 38 patients at one month after the end of a course of carbimazole/T3 therapy for Graves' disease. Despite the increased sensitivity of the IRMA assay a TSH measurement at this stage was found to be of no predictive value, in contrast to estimation of serum TRAb levels which correctly predicted relapse and remission in 90% of patients.
authors.affiliation: University Department of Medicine, Royal Infirmary, Glasgow, UK.
authors.forename: R
authors.initials: R
authors.lastname: Wilson
authors.forename: C G
authors.initials: CG
authors.lastname: Semple
authors.forename: A M
authors.initials: AM
authors.lastname: Reid
authors.forename: A C
authors.initials: AC
authors.lastname: Glen
authors.forename: J H
authors.initials: JH
authors.lastname: McKillop
authors.forename: J A
authors.initials: JA
authors.lastname: Thomson
mesh_terms: D001323:Autoantibodies / Q000032:analysis; D002231:Carbimazole / Q000627:therapeutic use*; D006801:Humans; D011863:Radioimmunoassay; D011989:Receptors, Thyrotropin / Q000276:immunology; D012008:Recurrence; D012074:Remission Induction; D013971:Thyrotoxicosis / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D013972:Thyrotropin / Q000097:blood*
chemical_list: D001323:Autoantibodies; D011989:Receptors, Thyrotropin; D002231:Carbimazole; D013972:Thyrotropin